It is worth mentioning that a phase 2 randomized placebo-controlled trial was recently launched, enrolling 160 participants at high risk for ASCVD with serum Lp(a) levels above 125 nmol/L (58 mg/dL). Here, LPA is linked to atherosclerosis.